- Home
- SPOK vs AVIR Comparison
SPOK vs AVIR Comparison
Compare SPOK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPOK | AVIR |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 450.9M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPOK | AVIR |
|---|---|---|
| Price | $11.21 | $5.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $14.00 | $8.00 |
| AVG Volume (30 Days) | 158.7K | ★ 495.1K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | 2.74 | ★ 3.00 |
| EPS | ★ 0.75 | N/A |
| Revenue | $139,708,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.80 | ★ N/A |
| Revenue Growth | ★ 1.49 | N/A |
| 52 Week Low | $10.81 | $2.46 |
| 52 Week High | $19.31 | $6.45 |
Technical Indicators
Market Signals| Indicator | SPOK | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 62.31 |
| Support Level | N/A | $3.33 |
| Resistance Level | $13.87 | $6.45 |
| Average True Range (ATR) | 0.26 | 0.28 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 55.43 | 83.10 |
Price Performance
Historical ComparisonAbout SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.